NCT05640999 2026-04-14
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Canadian Cancer Trials Group
Phase 2 Recruiting
Clinical Trials
13 trialsNCT01244789 2026-04-13
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Danish Gynecological Cancer Group
Phase 2 Active not recruiting
NCT02275533 2026-04-13
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07513324 2026-04-07
Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT01251861 2026-03-31
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05601440 2026-03-27
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07472478 2026-03-16
GIVEN
Guangdong Provincial People's Hospital
Phase 2 Not yet recruiting
NCT06378346 2026-02-23
GU-01
University of Illinois at Chicago
Phase 2 Recruiting
NCT07405476 2026-02-12
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
Phase 2 Not yet recruiting
NCT03516617 2026-02-09
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Recruiting
NCT03059485 2026-02-04
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT05633615 2026-02-02
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Phase 2 Recruiting
NCT05894083 2026-02-02
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
University of Michigan Rogel Cancer Center
Phase 2 Recruiting